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Background: Dihydroartemisinin (DHA) is a component of artemisinin-based combination therapy (ACT), which is
widely recommended for treatment of uncomplicated falciparum malaria. DHA is also the main metabolite of
artemether and artesunate, both of which are used in ACT. Due to auto-induction metabolism, declining plasma
concentrations after the repeated dosing have been reported for artemisinin (Qing-hao-su) and artemether. This study
was designed to evaluate the potential auto-induction metabolism of DHA in healthy Chinese adults after multiple oral
doses of DHA. The polymorphic effects of UGT1A9 (I399C>T) and UGT2B7*2 (802C>T), the major enzymes involved in
the metabolism of DHA, on the pharmacokinetic profiles of DHA and its metabolite was also studied.
Methods: Sixteen healthy Chinese subjects (four I399TT/802CC, four I399CC/802TT, four I399TT/802TT and four I399CT/
802CT) received four recommended oral doses of Artekin, an ACT containing DHA (80 mg/dose) and piperaquine
(PQ; 640 mg/dose), at 0, 6, 24 and 32 h. Plasma samples were analysed for DHA and its metabolite using a validated
liquid chromatography tandem mass spectrometric (LC-MS) method.
Results: DHA and its glucuronidated metabolite DHA-Glu were detected in human plasma after oral administration
of DHA-PQ. Compared with the first dose, the AUC0-t of the parent drug DHA decreased significantly (P<0.01) with
increased oral clearance (CL/F) after each repeated dose of DHA-PQ, whereas its metabolite DHA-Glu did not change
(P>0.05) in AUC0-t or Cmax. The phase II metabolic capability, calculated by the AUC0-t ratio of DHA-Glu to the parent
drug DHA, increased 1.5-fold (90% CI, 1.3-1.7), 1.2-fold (90% CI, 1.1-1.3) and 1.7-fold (90% CI, 1.5-1.8) after the second,
third and fourth dose, respectively. No polymorphic effect was found for UGT1A9 (I399C>T) and UGT2B7*2 (802C>T) on
the pharmacokinetic profiles of DHA and its metabolite DHA-Glu.
Conclusions: The auto-induction phase II metabolism of DHA was present in healthy Chinese subjects after the
recommended two-day oral doses of DHA-PQ (Artekin). The metabolic capability could recover after a 12-h dosing
interval, which suggested that the alternative common three-day regimen (once daily) for DHA-PQ could probably lead
to higher bioavailability of DHA. The polymorphism of UGT1A9 (I399C>T) and UGT2B7*2 (802C>T) may not be a
concern during the treatment with DHA.
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Artemisinin-based combination therapy (ACT) containing
dihydroartemisinin (DHA), artemether or artesunate is the
recommended treatment for uncomplicated Plasmodium
falciparum malaria by the World Health Organization
(WHO). DHA (Figure 1) is also the major active metab-
olite of its methyl ether (artemether) and hemisuccinate
ester artesunate [1,2]. Because of its relatively low cost,
high efficacy and good tolerability, DHA-piperaquine
(Artekin®) has been widely used for ACT [3]. The
current manufacturer’s recommendation for Artekin is
a two-day treatment, which contrasts with the three-day
recommended for all artemisinin-based combinations
by WHO. The compressed dosing regimen (four doses
over two days) for this DHA-PQ combination may
shorten the treatment period. However, a shorter dose
regimen might not be effective in some areas and may
cause DHA resistance to emerge more quickly. Several
reports have investigated the treatment efficacy using
the three-day and two-day regimen of DHA-PQ [4,5].
The pharmacokinetic and pharmacogenetic studies of
DHA could be of great importance in determining the
clinical efficacy and optimization of dose regimens for
DHA-PQ. DHA underwent extensive metabolism, and
approximately 90% of dose was recovered from rat
blood, urine and faeces in form of conjugated meta-
bolites [6]. The phase II metabolite DHA-Glu is an im-
portant metabolite of DHA [7], and more importantly it
possesses high-to-moderate anti-malarial activity [8].
Although, the disposition of the parent drug DHA has
been well studied, limited information was available for
the pharmacokinetic profile of the metabolite DHA-
Glu in humans. In addition, large inter-individual varia-
tions in the pharmacokinetics of DHA have been

















Figure 1 Structures of dihydroartemisinin (DHA), the glucuronide of DArtemisinin drugs (Qing-hao-su and artemether,)
showed time-dependent pharmacokinetics in both
healthy volunteers and infected patients as a several-
fold decrease in plasma concentration of the parent
drug with a corresponding increase in oral clearance
after repeated oral administrations [11,12]. However,
DHA and artesunate showed less convincing evidence for
this time-dependency [13-15]. Auto-induction of QHS
metabolism, which was mediated primarily by CYP2B6
and CYP3A4, has been implicated as the underlying
mechanism of the time dependent pharmacokinetics of
QHS [16,17]. The formation of the major metabolite of
DHA (DHA-Glu) was mainly catalyzed by UGT1A9 with
a minor role of UGT2B7 [7], which indicated that induc-
tion of UGT1A9 and/or UGT2B7 may be involved in
the potential auto-induction metabolism-mediated time-
dependent pharmacokinetics of DHA.
There is limited information on the pharmacogenetics
of anti-malarial agents except for a study, which showed
that the polymorphisms of several isoenzyme genes
(CYP2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4 and 3A5) were
not associated with the elimination of DHA, artemether
or artesunate in malarial patients [18]. However, the poly-
morphic effect of UGT1A9 and UGT2B7 on the pharma-
cokinetics of DHA has not been studied. Among the
mutants present in Asians with a relatively high frequency
(>5%), UGT1A9 (I399C > T), UGT2B7*2 (802C > T) and
UGT2B7*3 (211G > T) have been reported to be asso-
ciated with changed enzyme activity [19,20].
The main object of the present study was to evaluate
the potential auto-induction phase II metabolism of
DHA during a recommended two-day oral administra-
tion of a fixed ACT (Artekin). The pharmacokinetic
profiles of DHA and its major metabolite DHA-Glu in
healthy Chinese were studied. The effect of UGT1A9
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tics was also investigated.
Methods
Chemicals and reagents
Artekin tablets were purchased from Chongqing Holley
Healthpro Pharmaceutical Co., Ltd. (Chongqing, China).
DHA and QHS (as internal standard) were purchased
from Kunming Pharmaceutical Co. (purity >99.0%, Yunnan,
China). DHA glucuronide (DHA-Glu, Figure 1) was
synthesized in the laboratory, and its structure was con-
firmed by HR-MS, 1H-NMR and 13C-NMR spectros-
copy. Acetonitrile and methanol (HPLC grade) were
purchased from Fisher Chemicals (Fairlawn, NJ, USA).
All other chemicals used were purchased from Sigma-
Aldrich or Thermo Fisher Scientific.
Instrumentation
All LC-MS experiments were carried out on a Thermo
Electron LTQ-Orbitrap XL hybrid mass spectrometer
(ThermoFinnigan, Bremen, Germany) equipped with an
electrospray ionization interface. An Accela HPLC sys-
tem (ThermoElectron) was equipped with an autosam-
pler, a vacuum degasser unit, and a quaternary pump.
The mass spectrometric and chromatographic condi-
tions were shown in a previous report [21]. In brief, the
high resolution full scan mode across an m/z range that
bracketed DHA and its metabolite was used, and the re-
solving power was 15,000. Extracted ion chromatograms
(EICs) of m/z 302.196 for DHA, m/z 478.228 for DHA-
Glu, and m/z 283.154 for QHS, the internal standard
(IS), with a 10 ppm range centered on the exact m/z
value were generated for quantitation. Chromatographic
separation was achieved on a Luna ODS C18 column
(150 × 2.1 mm i.d., 5 μm; Phenomenex, Torrance, CA).
The mobile phase consisted of acetonitrile/methanol/
5 mM aqueous ammonium acetate containing 0.05% (v/v)
formic acid (55:30:15, v/v), delivered isocratically at a flow
rate of 0.35 mL/min. The autosampler was set at 4°C.
Quantification of DHA and its metabolite DHA-Glu
Plasma samples were subjected to a protein precipitation
extraction process, which was performed on ice. A
100 μL aliquot of human plasma was mixed with 200 μL
of IS (4 μM, prepared in acetonitrile) and 25 μL of
acetonitrile. The mixture was mixed and centrifuged at
3,000 g for 10 min. Aliquots (20 μL) of the solution were
injected onto LC-MS analysis. For calibration prepa-
ration, 100 μL of drug-free plasma was mixed with
25 μL of stock solution (DHA and DHA-Glu) and
200 μL of IS. This mixture was treated as above. The
calibration graph was plotted by least-squares linear re-
gression of the peak-area ratios (DHA or DHA-Glu to
IS) against concentrations of DHA or DHA-Glu. Matrixmatched calibration standards were obtained with con-
centrations of 40–4000 nM for DHA and DHA-Glu in
plasma. QC samples were obtained with three concen-
tration levels (100, 1000 and 3200 nM) in plasma.
Plasma samples were diluted with blank plasma and rea-
nalysed when the concentration of DHA-Glu was higher
than the upper limit of quantification.
Method validation
The method was evaluated through linearity, intra- and
inter-day precision and accuracy. The accuracy and pre-
cision of the method were assessed by determining QC
samples using six replicated preparations of plasma sam-
ples at three concentration levels (100, 1000 and 3200
nM) on three separate days. The lower limit of quantifi-
cation (LLOQ) represents the lowest concentration of
the analyte over the linear range that can be determined
with acceptable precision and accuracy.
Bench-top stability of DHA and DHA-Glu was
assessed by leaving the QC samples of two different con-
centrations (100 and 3200 nM) on ice for 1 hour. The
stability of samples in autosampler vials was assessed at
4°C for 8 hours. The stability of DHA and DHA-Glu in
human plasma after three freeze-thaw cycles and storage
under −80°C for 1 month was also evaluated.
Drug administration and sample collection
The experiment followed guidelines of the Declaration
of Helsinki for humans. The experimental protocol was
approved by the Ethics Committee of Shandong Univer-
sity (Jinan, China) and the Institutional Review Board of
Qilu Hospital (Shandong University, China). The clinical
project was performed at Qilu Hospital (Jinan, China).
Fifty-eight healthy and non-smoking male volunteers
(18–24 years; body mass index of 19–24 kg/m2) were ge-
notyped for UGT1A9 (I399C > T), UGT2B7 (211C > T;
802C > T) and CYP2B6 (516G > T) by polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP). The genotype of each gene was determined by
Sangon Biotech (Shanghai, P.R. China), and the method
was pre-validated by the sequencing technique. The infor-
mation on the primers, incision enzymes and PCR prod-
ucts for each gene is shown in Additional file 1. Sixteen
subjects (four I399TT/802CC, four I399CC/802TT, four
I399TT/802TT and four I399CT/802CT) with wild type
of UGT2B7 (211CC) and CYP2B6 (516GG) were enrolled
in the clinical trial, and written informed consent was pro-
vided prior to this study. They were in good health as
assessed by medical history, physical examination and la-
boratory analysis (complete blood count, total bilirubin,
direct bilirubin, serum creatinine, blood urea nitrogen, ala-
nine aminotransferase, and serum albumin).
Sixteen subjects were treated with four oral doses of
DHA-PQ tablets (Artekin) according to manufacturer’s
Zang et al. Malaria Journal 2014, 13:478 Page 4 of 9
http://www.malariajournal.com/content/13/1/478recommendation (80 mg DHA plus 640 mg PQ for each
dose at 0, 6, 24 and 32 h). Two subjects (one I399TT/
802CC and one I399TT/802TT) did not receive the
third and fourth doses due to scheduling conflicts. The
subjects were fasted overnight (the first and third doses)
or 2 hours (the second and fourth doses) before drug ad-
ministration and for a further 2 hours after dosing. Food
was provided at 2, 4 and 10 h each day. Water was freely
available during experiments. Venous blood samples
(2 mL) for determination of DHA and its metabolite
DHA-Glu were taken from an indwelling intravenous
catheter at 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 6.5, 7.0,
7.5, 8.0, 8.5, 9.0, 10.0, 12.0, 24.0, 24.5, 25.0, 25.5, 26.0,
27.0, 28.0, 30.0, 30.5, 31.0, 31.5, 32.0, 32.5, 33.0, 34.0,
36.0 and 48.0 h, and collected in anticoagulant tubes
drawn from forearm venous catheters before and after
oral administration of DHA-PQ. Plasma was separated
by centrifugation at 3,000 g for 10 min at 4°C. The
plasma was stored at −80°C until analysis.
Pharmacokinetics and statistical analysis
The peak plasma concentration (Cmax) and time-to-peak
concentration (Tmax) were obtained from experimental
observations. The other pharmacokinetic parameters
were analysed by non-compartmental model using the
program TOPFIT (version 2.0; Thomae GmbH, Germany).
The area under the plasma concentration-time curve
(AUC0-t) was calculated using the linear trapezoidal rule
to approximately the last point. Total oral body clearance
(CL/F) was calculated as dose/AUC0-t. The inter-
individual variability of pharmacokinetic parameters of
DHA was calculated by the difference between individual
values and mean values. The metabolic capability was
evaluated by the AUC0-t ratio (AUCDHA-Glu/AUCDHA) of
DHA-Glu to the parent drug DHA.
Results were expressed as mean ± SD. Induction cap-
ability, expressed as DHA CL/FRepeated dose/CL/F1st dose,
was shown as fold change (90% CI), and Tmax was
expressed as the median (range). Statistical calculations
were performed with SPSS (version 19.0, SPSS Inc., Chi-
cago, IL, USA). The two-tailed t-test was used for paired
comparison of the pharmacokinetic parameters between
the first dose and repeated doses after logarithmic trans-
formation. The comparison of Tmax for the different
treatment groups was performed using the Wilcoxon
signed-rank test. Geometric mean ratios with 90% confi-
dence intervals (CIs) were calculated after log transform-
ation of within-subject data. The mean changes in
pharmacokinetic parameters among different genotype
groups were compared using one way ANOVA with re-
peated measures. A greater than 1.2-fold increase in CL/
F of DHA, relative to the control, was defined to be in-
duction. The acceptable level of significance was estab-
lished at P < 0.05 or P < 0.01.Results
LC-MS method for determination of DHA and its
metabolite DHA-Glu
Under optimized HPLC conditions, DHA and its major
metabolite DHA-Glu were eluted within 10 min (Figure 2).
Blank human plasma from six lots showed no significant
interfering peaks at the retention times of each analyte.
The calibration curves of DHA and DHA-Glu were linear
over the concentration range of 40–4000 nM with corre-
lation coefficients r > 0.99 when evaluated by weighed
(1/x2) least-squares linear regression. The lower limits of
quantification (LLOQ) of DHA and DHA-Glu in human
plasma were established at 40 nM (Figure 2A). The preci-
sion and accuracy of this method indicated that all coeffi-
cients of variation at each concentration level were below
15%. Previous studies have shown that DHA was not
stable at room temperature [22], and plasma samples were
processed on ice and stored at low temperature in the
present study. There was no significant difference (<15%)
between the responses of standards at time zero and after
three freeze-thaw cycles, storage of plasma on ice for at
least two hours, or after storage under −80°C for one
month, indicating that they were stable under these condi-
tion. Processed samples were stable (%CV <15%) for at
least eight hours in the autosampler tray.
Pharmacokinetics of DHA and its metabolite DHA-Glu
After oral administration of DHA to human subjects,
DHA and its major metabolite DHA-Glu could be de-
tected (Figure 2B and Figure 2C). The mean plasma
concentration-time profiles of DHA and its metabolite
DHA-Glu in healthy subjects are shown in Figure 3, and
the pharmacokinetic parameters are given in Table 1.
Sixteen healthy subjects received four recommended
lower doses of DHA (1.2 mg/kg/dose). After the first
dose, DHA was rapidly eliminated, with a high mean
CL/F (3.3 L/h/kg) and a short T1/2 (0.9 h). The dose-
normalized AUC0-t of DHA was 0.32 ± 0.10 h⋅kg/L after
a single oral dose of DHA. The inter-individual variabi-
lity (%CV) was observed in DHA pharmacokinetic
parameters, including AUC0-t (2.8-58.9%). The time-
dependent pharmacokinetics existed for DHA in 12 out
of 16 subjects (Figure 4), and four oral doses of DHA-
PQ resulted in a 34.4% decrease in AUC compared with
the first dose. The corresponding CL/F value signifi-
cantly increased 1.6-fold ((90% CI, 1.4-1.7). Compared
with the first dose, the Cmax of DHA decreased signifi-
cantly (P < 0.01) after the second and fourth doses but
not after the third dose. The volume of distribution (Vd)
of DHA increased significantly (P < 0.01) after the re-
peated dose (Table 1). Tmax and T1/2 of DHA did not
change (P > 0.05) after repeated drug dosing.
The metabolite DHA-Glu was detected in a relatively
high level (mean Cmax of 2.5 μM). Compared with the

























































































































Figure 2 Representative full-scan chromatograms of (A) a blank human plasma sample spiked with dihydroartemisinin (DHA; 40 nM),
the glucuronide of DHA (DHA-Glu; 40 nM) and IS (QHS, 4 μM); (B) a human (subject H3) plasma sample at 1.5 h after the first oral dose
of DHA (80 mg); and (C) a human (subject H3) plasma sample at 1.5 h after the fourth oral dose of DHA (80 mg). I: DHA (m/z 302.1962);
II: the glucuronide of DHA (m/z 478.2283); III: IS (m/z 283.1540).
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did not change significantly (P > 0.05) after repeated oral
doses of DHA-PQ (Table 1 and Figure 4). The metabolic
capability, calculated by AUCDHA-Glu/AUCDHA, increased
to 1.5-fold (90% CI, 1.3-1.7) after a second repeated oral
dosing. After a 12-h dosing interval, the metabolic ca-
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Figure 3 Mean (+S.D.) plasma concentration-time profiles of dihydroa
healthy Chinese adults (n = 16) following four recommended oral dosincreased to 1.7-fold after the last dose (Figure 4). A large
inter-individual variability of the metabolic capability
existed for DHA in 16 subjects (%CV, 2.4-128.4%). The
AUC ratio increased 1.6-fold in 12 out of 16 subjects after
the second dose. The third and fourth doses led to an in-
crease of the metabolic capability in 7 (1.4-fold) and 12
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rtemisinin (DHA) and the glucuronide of DHA (DHA-Glu) in
es of DHA (80 mg/dose).
Table 1 The main pharmacokinetic parameters of dihydroartemisinin (DHA) and its metabolite (DHA-Glu) in healthy
Chinese subjects (n = 16) after four recommended oral doses of DHA (80 mg/dose)
AUC0-t/Dose
(h⋅kg/L)
Cmax (nM) Tmax (h) T1/2 (h) CL/F (L/h/kg) Vd (L/kg)
DHA 1st dose 0.32 ± 0.10 648.37 ± 264.69 1.6 (1.0-2.5) 0.9 ± 0.2 3.33 ± 1.06 4.08 ± 1.36
2nd dose 0.24 ± 0.07** 442.34 ± 156.17** 1.9 (1.0-4.0) 0.9 ± 0.3 4.35 ± 1.33** 5.26 ± 1.98**
3rd dose 0.26 ± 0.09** 569.48 ± 240.80 1.8 (0.5-3.0) 0.9 ± 0.1 4.13 ± 1.35* 4.97 ± 1.53**
4th dose 0.21 ± 0.06** 410.78 ± 151.93** 2.1 (1.0-4.0) 1.1 ± 0.6 4.65 ± 1.37** 6.65 ± 2.60**
DHA-Glu 1st dose 1.51 ± 0.42 2495.27 ± 756.66 1.6 (1.0-2.5) 1.2 ± 0.3 N.A. 1.11 ± 0.43
2nd dose 1.63 ± 0.41 2779.61 ± 809.14 2.1 (1.0-4.0) 1.2 ± 0.4 N.A. 0.99 ± 0.39
3rd dose 1.39 ± 0.33 2395.57 ± 697.35 2.1 (1.0-3.0) 1.2 ± 0.1 N.A. 1.17 ± 0.27
4th dose 1.61 ± 0.31 2624.44 ± 903.36 2.2 (1.5-4.0) 1.1 ± 0.2 N.A. 1.01 ± 0.39
Geometric mean ratios for
DHA (90% CI)
2nd/1st dose 0.77 (0.73-0.81)** 0.73 (0.64-0.83)** N.A. 1.00 (0.90-1.09) 1.31 (1.24-1.38)** 1.32 (1.17-1.46)**
3rd/1st dose 0.83 (0.74-0.91)** 0.95 (0.75-1.15) N.A. 0.98 (0.91-1.05) 1.27 (1.11-1.43)* 1.24 (1.09-1.38)**
4th/1st dose 0.73 (0.66-0.80)** 0.70 (0.55-0.85)** N.A. 1.22 (0.95-1.49) 1.42 (1.28-1.55)** 1.65 (1.37-1.93)**
AUCDHA-Glu/AUCDHA (90% CI) 2nd/1st dose 1.49 (1.30-1.69)* N.A. N.A. N.A. N.A. N.A.
3rd/1st dose 1.18 (1.05-1.31) N.A. N.A. N.A. N.A. N.A.
4th/1st dose 1.66 (1.46-1.85)** N.A. N.A. N.A. N.A. N.A.
N.A., not acquired.
*P < 0.05; **P < 0.01 (compared with the first dose).
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UGT2B7 (802C > T)
After oral administration of DHA-PQ, the dose-
normalized AUC0-t of DHA and its metabolite DHA-Glu
did not show difference (P > 0.05) in subjects with diffe-
rent UGT1A9 (I399C > T) or UGT2B7 (802C > T) geno-
types. No association was observed between two UGT
genotypes and the induction capability, calculated by fold
changes of CL/F after the first and fourth doses of DHA-
PQ. The metabolic capability (AUCDHA-Glu/AUCDHA) and
the induction ratio (CL/F4th dose/CL/F1st dose) in healthy
subjects with different UGTs genotypes are shown in
Table 2.
Discussion
Several published studies have evaluated the phar-
macokinetics of the parent drug DHA in healthy sub-
jects and patients, after oral administration of DHA
either as monotherapy or ACT [10,13,14]. These find-
ings suggest that PQ should not influence the pharma-
cokinetic characteristics of DHA when co-administered
in the proposed fixed oral combinations [10]. In the
present study, the pharmacokinetics of DHA and its
major metabolite DHA glucuronide after oral adminis-
tration of DHA-PQ was investigated in healthy subjects,
which could enable us to eliminate the influence of
diseases or concomitant medication. The polymorphic
effects of UGT1A9 and UGT2B7, the major UGT en-
zymes involved in the metabolism of DHA, on the auto-
induction metabolism-mediated pharmacokinetics of
DHA were also studied.The dose-normalized AUC0-t (0.32 ± 0.10 h⋅kg/L) of
DHA obtained from a single oral dose of DHA in the
present study was similar to reported values in healthy
subjects (0.3-0.4 h⋅kg/L) [10,14]. The AUC and Cmax of
DHA have been found much higher (2–5 fold) in ma-
laria patients compared with healthy subjects [23], pro-
bably due to the lower hepatic clearance caused by
malarial infection. Similar to Qing-hao-su, the time-
dependent decrease of DHA plasma concentrations has
also been observed in healthy volunteers after repeated
doses of DHA [14]. A five-day oral monotherapy regi-
men of DHA could lead to reduced plasma levels of
DHA in Vietnamese patients on the final day of the
treatment but not within the first two days, which was
probably due to the recovery of drug elimination pro-
cesses during the convalescent phase of the disease [13].
The present results showed that the time-dependent
pharmacokinetics existed for DHA even after a second
oral dose of DHA-PQ. The Cmax of DHA obtained from
the first dose was 1.7-fold of the fourth dose, which was
in agreement with a previous study [14]. The metabolic
capability, calculated by AUC ratio of DHA glucuronide
to DHA, increased in most subjects after four oral doses
of DHA-PQ. Two subjects did not show higher AUC ra-
tio probably due to their low enzyme activity. Compared
with Qing-hao-su and artemether, DHA has a smaller
inductive potential [16,24]. The time-dependent pharma-
cokinetics may be a common feature for artemisinin
drugs. However, artesunate did not show convincing evi-
dences [15,25], which may be caused by its rapid absorp-
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Figure 4 Individual values for pharmacokinetic parameters (AUC/dose, CL/F and AUCDHA-Glu/AUCDHA) of dihydroartemisinin (DHA) and
its metabolite DHA glucuronide (DHA-Glu) in healthy Chinese (n = 14-16 for each dose) after four recommended oral doses of DHA
(80 mg/dose) (the average value was labeled in short line).
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indicated that the volume of distribution of DHA in-
creased in the same proportion as its plasma clearance.
In this study, the metabolic capability increased after
two repeated doses of DHA in the first day and then de-
creased on the second day after a 12-h dosing interval,
which suggested that the metabolic capability could re-
cover after multiple oral administrations of DHA. These
results suggested that the oral bioavailability of DHA
could be higher if DHA were given in a longer dosing
interval, such as once daily. A three-day regimen for
DHA-PQ (2 mg/kg DHA and 15 mg/kg PQ) has been
found well tolerated and more effective than a two-dayTable 2 The main pharmacokinetic parameters of dihydroarte
Chinese subjects with different UGT1A9 (I399C > T) and UGT2
four recommended oral doses of DHA (80 mg/dose)
CL/F1st dose (L/h/kg) CL/F4th dose (L/h/kg)
I399CC/802TT 3.00 ± 0.84 4.72 ± 1.87
I399TT/802CC 3.45 ± 0.71 4.44 ± 1.34
I399TT/802TT 2.84 ± 0.98 4.83 ± 1.54
I399CT/802CT 4.05 ± 1.49 4.60 ± 1.34
MR: metabolic ratio, calculated by AUCDHA-Glu/AUCDHA.regimen [4,5]. Oral administration of DHA-PQ with a
common three-day course regimen (once daily) could be
an alternative to the present recommended dose regimen.
A large inter-individual variation in pharmacokinetic
parameters has been found for DHA, which included
the Cmax (2–54 fold), AUC (2–26 fold) and CL/F (2–22
fold) [10,13,14,23]. One explanation is the polymorphism
of CYP2B6 and UGTs. CYP2B6 is involved in the phase
I metabolism of artemisinin drugs [26], and 516G > T
(CYP2B6*6) is the most commonly observed SNP, which
was associated with reduced CYP2B6 protein expression
and activity. Glucuronidation was the main biotransfor-
mation pathway for DHA, and the predominant isoformsmisinin (DHA) and its metabolite (DHA-Glu) in healthy
B7 (802C > T) genotypes (n = 3-4 for each group) after
CL/F4th dose/CL/F1st dose (90% CI) MR1st dose MR4th dose
1.53 (1.08-1.98) 4.34 ± 0.71 7.90 ± 2.08
1.39 (1.04-1.74) 5.79 ± 2.72 7.05 ± 4.05
1.61 (1.35-1.87) 3.89 ± 1.42 8.21 ± 2.15
1.17 (0.95-1.40) 6.94 ± 3.52 9.25 ± 3.58
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http://www.malariajournal.com/content/13/1/478involved were UGT1A9 (Km, 32 μM) and UGT2B7(Km,
438 μM) [7]. In order to optimize the dose regimen for
DHA and elucidate the factors leading to its inter-
individual variability, the influence of UGT1A9 and
UGT2B7 polymorphism on the pharmacokinetics of DHA
was also investigated in this study. Healthy subjects with
wild-type CYP2B6 were selected to avoid the potential in-
fluence of CYP2B6*6, even though CYP2B6*6 polymor-
phism has not been detected for Qing-hao-su derivatives
(DHA, artemether and artesunate) in Cambodia and
Tanzania patients [18].
Considering that reported mutations of UGT1A9
(G8A, T98C, G766A; [27]) are rare in Asian populations,
the polymorphism of these SNPs may not influence DHA
clearance in this study. Functional SNPs (I399C >T) were
more commonly observed in the UGT1A9 gene in Asian
populations, which could confer increased protein expres-
sion [19]. Although another variant of UGT1A9 (C-440 T/
C-331 T) was also associated with significantly enhanced
glucuronidation [28], it was not considered in the present
study due to its low frequency of homozygous mutant (3-
4%). So far, two major nonsynonymous SNPs have been re-
ported for UGT2B7, which include C802T and G211T
[19,20]. UGT2B7 802C >T emerged as a variant allele in all
the populations with the highest frequency [20]. It seemed
that the effect of C802T on the glucuronidation was
substrate-dependent [20]. The other UGT2B7 variant fre-
quently observed is 211G >T, which was involved in the
metabolism of many substrates, such as morphine and
MPA [19]. The present study showed that neither UGT1A9
(I399C >T) nor UGT2B7 (802C >T) contributed to the
inter-individual variability in the pharmacokinetics of DHA.
Several factors may impose a degree of uncertainty in
the present study. The different fasted state between the
first/third (fasted overnight) and second/fourth dose
(fasted for 2 hours) could probably influence the bioavai-
lability and/or hepatic clearance of DHA. The data was
obtained between each UGT genotype group with four
subjects, and the influence of these SNPs needs to be con-
firmed in a larger population. Due to rare wild-type alleles
for both UGT1A9 and UGT2B7, the effect of UGT1A9
(or UGT2B7) was evaluated in subjects with the genotype
of I399CC/802TT (or I399TT/802CC) and I399TT/
802TT. In addition, we could not exclude the possibility
that other genetic factors (CYPs, UGTs, transporters and
nuclear receptors) not tested in this study might contri-
bute to inter-individual variability in DHA pharmacokine-
tics. The PQ elimination mechanism is still unknown, and
its potential effect on DHA elimination due to drug-drug
interaction deserves further studies.
Conclusions
The results showed the presence of auto-induction
phase II metabolism for DHA in healthy Chinese. Lowerexposure to DHA and higher metabolic capability to
form its metabolite DHA-Glu were observed after re-
peated oral doses of DHA. From the point of auto-
induction metabolism, a longer dosing interval (such as
once daily) is an alternative to the present recommended
dose regimen for DHA-PQ. The polymorphism of
UGT1A9 (I399C > T) and UGT2B7 (802C > T) may not
be a concern during the treatment with DHA.
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